The long-term objective is to improve recruitment, adherence and retention in clinical trials particularly among hard-to-reach populations of women, minorities and intravenous drug users.
The specific aims of this study are as follows: (1) To determine if sociodemographic factors influence participation in clinical trials for HIV-related drugs; (2) After accounting for sociodemographic factors, to determine if type of clinical trial, HIV-related medical status, and behavioral factors influence agreement to participate in a clinical trial among a population of persons invited to participate; (3) To develop a psychosocial profile of clinical trial participants, including knowledge, attitudes and behavior associated with recruitment, adherence and retention in clinical trials. And, in an exploratory way, to investigate psychosocial and attitudinal factors among persons who decline participation in a clinical trial; (4) Prospectively, to determine which of the above sociodemographic, medical, behavioral or psychosocial factors (and combinations of factors) predict adherence and retention in clinical trials among those enrolled; (5) To examine whether participation in clinical trials, per se, influences health-relevant attitudes, behavior, and outcomes. Data will be collected from HIV/AIDS patients who agree (experimental group) and disagree (comparison group) to participate in clinical trials. Data will be gathered from existing medical records for all subject (N=400-500). In addition, interviews will be conducted by a trained clinical interviewer: 1 interview with a select group of comparison group members (n=100), and 3 interviews over the course of the clinical trial for the experimental group members (n=100). All experimental group members will be interviewed at enrollment and 3 months post-enrollment to enable comparative prospective analysis; the timing of a third interview is dependent on type of trial (phase I vs. II/III) and completion versus termination of trial. A series of hierarchical logistic regression models will be used to analyze these data.

Project Start
Project End
Budget Start
1995-10-01
Budget End
1996-09-30
Support Year
4
Fiscal Year
1996
Total Cost
Indirect Cost
Name
Yale University
Department
Type
DUNS #
082359691
City
New Haven
State
CT
Country
United States
Zip Code
06520
Landry, M L; Stanat, S; Biron, K et al. (2000) A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates. Antimicrob Agents Chemother 44:688-92
McCance-Katz, E F; Rainey, P M; Jatlow, P et al. (1998) Methadone effects on zidovudine disposition (AIDS Clinical Trials Group 262). J Acquir Immune Defic Syndr Hum Retrovirol 18:435-43
Ickovics, J R; Meisler, A W (1997) Adherence in AIDS clinical trials: a framework for clinical research and clinical care. J Clin Epidemiol 50:385-91
Landry, M L; Cohen, S; Huber, K (1997) Comparison of EDTA and acid-citrate-dextrose collection tubes for detection of cytomegalovirus antigenemia and infectivity in leukocytes before and after storage. J Clin Microbiol 35:305-6
Japour, A J; Lertora, J J; Meehan, P M et al. (1996) A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team. J Acquir Immune Defic Syndr Hum Retrovirol 13:235-46
Griffith, B P; Brett-Smith, H; Kim, G et al. (1996) Effect of stavudine on human immunodeficiency virus type 1 virus load as measured by quantitative mononuclear cell culture, plasma RNA, and immune complex-dissociated antigenemia. J Infect Dis 173:1252-5
Wetherill, P E; Landry, M L; Alcabes, P et al. (1996) Use of a quantitative cytomegalovirus (CMV) antigenemia test in evaluating HIV+ patients with and without CMV disease. J Acquir Immune Defic Syndr Hum Retrovirol 12:33-7
Skalski, V; Liu, S H; Cheng, Y C (1995) Removal of anti-human immunodeficiency virus 2',3'-dideoxynucleoside monophosphates from DNA by a novel human cytosolic 3'-->5' exonuclease. Biochem Pharmacol 50:815-21
Piras, G; Dutschman, G E; Im, G J et al. (1995) Action of uracil analogs on human immunodeficiency virus type 1 and its reverse transcriptase. Antimicrob Agents Chemother 39:539-41
Landry, M L; Ferguson, D; Cohen, S et al. (1995) Effect of delayed specimen processing on cytomegalovirus antigenemia test results. J Clin Microbiol 33:257-9

Showing the most recent 10 out of 13 publications